Loading patent…
AssigneeREGENXBIO Inc.
InventorsCurran Matthew Simpson, Stephen Yoo, Karen Fran Kozarsky, Rickey Robert Reinhardt, Laura A. Coruzzi
Estimating the term…
Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
1-7. (canceled)
An anti-human vascular endothelial growth factor (hVEGF) antigen-binding fragment produced by human retinal cells.
A glycosylated anti-hVEGF antigen-binding fragment, which:
An anti-hVEGF antigen-binding fragment, which contains a tyrosine-sulfation.
A pharmaceutical composition suitable for subretinal administration comprising a suspension of a recombinant viral vector encoding an anti-hVEGF antigen-binding fragment in a formulation buffer comprising a physiologically compatible aqueous buffer and a surfactant wherein the recombinant viral vector in the composition is capable of transducing human retinal cells upon subretinal administration.
A pharmaceutical composition suitable for subretinal administration comprising a suspension of a recombinant viral vector encoding an anti-hVEGF antigen-binding fragment in a formulation buffer comprising a physiologically compatible aqueous buffer and a surfactant wherein the recombinant viral vector in the composition is capable of transducing human retinal cells upon subretinal administration.
A method of manufacturing a recombinant viral vector comprising providing a host cell stably transformed with sequences encoding an anti-hVEGF antigen-binding fragment, wherein the recombinant viral vector is capable of transducing human retinal cells upon subretinal administration.
A method of manufacturing a recombinant viral vector comprising providing a host cell stably transformed with sequences encoding an anti-hVEGF antigen-binding fragment, wherein the recombinant viral vector is capable of transducing human retinal cells upon subretinal administration.
Dependencies are inferred from the claim text.